started · updated
AbbVie expands Oxford research facility and signs $1.37 billion drug deal
Pharmaceutical company AbbVie is expanding its research and development operations in Oxford, UK, through the establishment of a new 12,000 square foot facility. This expansion is part of a broader commitment of over £120 million invested in the UK life sciences sector, focusing on immunology, neuroscience, and oncology.
The Oxford site builds upon AbbVie’s 2022 acquisition of DJS Antibodies and aims to leverage the region's academic and clinical expertise. The company intends to use the facility to support human biology and reverse translation approaches to drug discovery.
In a separate development, AbbVie has entered into an exclusive global licensing agreement with Japan-based Nxera. The deal, valued at up to $1.37 billion, focuses on the development of a new treatment for inflammatory bowel disease (IBD).
Entities
AbbVie · DJS Antibodies · Nxera · Oxford